An oriented self-assembly biosensor with built-in error-checking for precise midkine detection in cancer diagnosis...

Area of Science:

• Biomedical Engineering
• Cancer Biomarkers
• Biosensor Technology

Background:

• Midkine (MDK) is a growth factor implicated in cancer progression and drug resistance.
• Serum MDK shows potential for non-invasive tumor detection, prognosis, and treatment monitoring.
• Current detection methods lack the sensitivity for widespread clinical application.

Purpose of the Study:

• To develop a highly sensitive and accurate biosensor for Midkine (MDK) detection.
• To create a versatile detection platform usable with various instruments, including mobile phones.
• To establish a novel tool for improved cancer diagnosis and prognostic evaluation.

Main Methods:

• Development of a triple-mode biosensor utilizing oriented self-construction and error-checking.
• Incorporation of biosynthesized quantum dots (BQDs) for antibody orientation and enhanced binding.
• Utilized Au@Pt nanorods-Ab2 (MF-Probe) as multifunctional probes for signal amplification.

Main Results:

• The biosensor demonstrated a wide linear range (5 fg/mL to 100 ng/mL) and a low limit of detection (1.620 fg/mL).
• The sensor successfully differentiated MDK levels in healthy donors versus cancer patients.
• Achieved superior sensitivity and lower LOD compared to existing ELISA kits.

Conclusions:

• The developed triple-mode biosensor provides a sensitive, rapid, and convenient method for MDK detection.
• This technology holds significant promise for early cancer diagnosis and prognostic assessment.
• The biosensor's versatility and performance suggest potential for clinical translation.